• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series.

作者信息

Martora Fabrizio, Picone Vincenzo, Fabbrocini Gabriella, Marasca Claudio

机构信息

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

出版信息

JAAD Case Rep. 2022 May;23:42-45. doi: 10.1016/j.jdcr.2022.03.008. Epub 2022 Mar 12.

DOI:10.1016/j.jdcr.2022.03.008
PMID:35308064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8916983/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/58bc4f75120f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/edf6566fca52/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/63923a401556/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/58bc4f75120f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/edf6566fca52/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/63923a401556/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6331/8987343/58bc4f75120f/gr3.jpg

相似文献

1
Hidradenitis suppurativa flares following COVID-19 vaccination: A case series.新冠病毒疫苗接种后化脓性汗腺炎发作：病例系列
JAAD Case Rep. 2022 May;23:42-45. doi: 10.1016/j.jdcr.2022.03.008. Epub 2022 Mar 12.
2
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab.与阿达木单抗治疗的化脓性汗腺炎患者发病和复发相关的因素。
Ital J Dermatol Venerol. 2022 Apr;157(2):137-141. doi: 10.23736/S2784-8671.21.06966-8. Epub 2021 May 13.
3
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.依奇珠单抗在化脓性汗腺炎患者中的疗效通过国际化脓性汗腺炎严重程度评分系统（IHS4）评估：SUNSHINE和SUNRISE试验的事后分析
J Eur Acad Dermatol Venereol. 2025 Aug;39(8):1421-1430. doi: 10.1111/jdv.20369. Epub 2024 Oct 19.
4
Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.阿达木单抗治疗化脓性汗腺炎的临床应答率和病情恶化。
Clin Exp Dermatol. 2020 Jun;45(4):438-444. doi: 10.1111/ced.14127. Epub 2019 Dec 24.
5
Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.居民能否充分评估化脓性汗腺炎的严重程度？主要评分系统的组内和组间可靠性评估。
Dermatology. 2020;236(1):8-14. doi: 10.1159/000501771. Epub 2019 Sep 5.
6
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.国际化脓性汗腺炎严重程度评分系统（IHS4）的制定与验证，一种新型动态评分系统，用于评估 HS 严重程度。
Br J Dermatol. 2017 Nov;177(5):1401-1409. doi: 10.1111/bjd.15748. Epub 2017 Oct 30.
7
Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.克林霉素与克林霉素加利福平治疗化脓性汗腺炎：临床和超声观察。
J Am Acad Dermatol. 2019 May;80(5):1314-1321. doi: 10.1016/j.jaad.2018.11.035. Epub 2018 Nov 28.
8
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.临床缓解率、安慰剂缓解率和显著相关的协变量取决于化脓性汗腺炎的结局测量选择：PIONEER 1 和 2 个体患者数据的事后分析。
J Am Acad Dermatol. 2020 May;82(5):1150-1157. doi: 10.1016/j.jaad.2019.12.044. Epub 2019 Dec 24.
9
The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting ("Ramadan Fasting") on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study.间歇性、限时昼夜节律禁食（“斋月禁食”）对化脓性汗腺炎的安全性和影响：一项多中心、观察性、交叉、先导、探索性研究的结果。
Nutrients. 2019 Aug 1;11(8):1781. doi: 10.3390/nu11081781.
10
Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.林可霉素对比克林霉素加利福平治疗化脓性汗腺炎：临床和超声评估。
Clin Exp Dermatol. 2021 Jan;46(1):96-102. doi: 10.1111/ced.14388. Epub 2020 Sep 17.

引用本文的文献

1
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature.化脓性汗腺炎的癌症风险：文献综述
Clin Cosmet Investig Dermatol. 2025 Mar 18;18:617-626. doi: 10.2147/CCID.S512373. eCollection 2025.
2
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes-A Review of the Literature.老年化脓性汗腺炎患者：临床和治疗结果——文献综述。
Medicina (Kaunas). 2024 Sep 6;60(9):1465. doi: 10.3390/medicina60091465.
3
Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?接种新冠疫苗会引发免疫介导的炎症性疾病吗？
J Clin Med. 2024 Aug 7;13(16):4617. doi: 10.3390/jcm13164617.
4
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report.司库奇尤单抗用于一名血液透析患者的重度化脓性汗腺炎：每2周一次300mg给药方案的疗效和安全性——病例报告
Clin Cosmet Investig Dermatol. 2024 May 30;17:1275-1279. doi: 10.2147/CCID.S468268. eCollection 2024.
5
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report.古塞库单抗治疗青少年化脓性汗腺炎的长期疗效：一例报告
Clin Cosmet Investig Dermatol. 2024 Feb 29;17:483-487. doi: 10.2147/CCID.S456817. eCollection 2024.
6
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.司库奇尤单抗用于阿达木单抗治疗失败的化脓性汗腺炎患者：一项52周的真实世界研究。
Clin Cosmet Investig Dermatol. 2024 Jan 23;17:159-166. doi: 10.2147/CCID.S449367. eCollection 2024.
7
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review.新型冠状病毒肺炎疫苗接种后玫瑰糠疹及玫瑰糠疹样皮疹：一项叙述性综述
Clin Cosmet Investig Dermatol. 2024 Jan 8;17:51-57. doi: 10.2147/CCID.S447834. eCollection 2024.
8
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature.COVID-19 疫苗接种对炎症性皮肤疾病和其他皮肤疾病的影响：已发表文献综述。
Viruses. 2023 Jun 23;15(7):1423. doi: 10.3390/v15071423.
9
The Impact of Telemedicine on Patients with Hidradenitis Suppurativa in the COVID-19 Era.远程医疗对 COVID-19 时代化脓性汗腺炎患者的影响
Healthcare (Basel). 2023 May 17;11(10):1453. doi: 10.3390/healthcare11101453.
10
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?常见炎症性皮肤病的远程皮肤病学：未来医学？
Life (Basel). 2023 Apr 18;13(4):1037. doi: 10.3390/life13041037.